Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
4.250
+0.195 (4.81%)
Jul 30, 2026, 3:08 PM EDT - Market open
Immuneering Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Immuneering stock has a consensus rating of "Strong Buy" and an average price target of $18.86. The average 1-year stock price forecast is 343.76% higher than the current stock price, while the lowest is $12 (+182.35%) and the highest is $30 (+605.88%).
Price Target: $18.86 (+343.76%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Immuneering stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho Securities | Mizuho Securities | Buy Reiterates $12 | Buy | Reiterates | $12 | +182.35% | Jul 13, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $17 | Buy | Initiates | $17 | +300.00% | Jul 8, 2026 |
| Needham | Needham | Buy Maintains $11 | Buy | Maintains | $11 | +158.82% | Jun 2, 2026 |
| Chardan Capital | Chardan Capital | Buy Reiterates $20 | Buy | Reiterates | $20 | +370.59% | May 19, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $12 | Buy | Maintains | $12 | +182.35% | Apr 21, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
19.50M
EPS This Year
-1.11
from -1.27
EPS Next Year
-1.29
from -1.11
EPS and Forward PE are based on non-GAAP adjusted numbers.